Global Japanese Encephalitis (JE) Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Japanese Encephalitis (JE) Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Japanese encephalitis (JE) is the leading cause of viral encephalitis in many Asian countries. JE virus is a flavivirus associated with dengue, yellow fever and West Nile virus and is transmitted by mosquitoes, causing infection. The virus is transmitted in an enzootic cycle (enzootic cycle) between mosquitoes, pigs, and/or waterfowl. Humans become infected when they are bitten by an infected mosquito. The disease occurs mainly in rural and peri-urban areas.

Japanese encephalitis vaccine is a vaccine that protects against Japanese encephalitis.

Market Overview:

The latest research study on the global Japanese Encephalitis (JE) Vaccine market finds that the global Japanese Encephalitis (JE) Vaccine market reached a value of USD 499.34 million in 2022. It’s expected that the market will achieve USD 658.15 million by 2028, exhibiting a CAGR of 4.71% during the forecast period.

Market Opportunities

Since the first discovery of JE vaccines in the 1930s, the JE vaccine industry has evolved from the original vaccine to live attenuated and inactivated vaccines as vaccine technology has advanced. Currently, polyvalent conjugate and combination vaccines are the main technological trends.
Moreover, in addition to the rising awareness of the disease, the increase in travel and tourism is one of the key factors contributing to the growth of the industry. The tropics are the most lucrative market due to high prevalence of JE in the tropics, expansion of government-led national immunization programs, growth in R&D investments, entry of new vaccine manufacturers from countries such as India and China, increase in tourist arrivals, medical tourism, etc. Moreover, increase in pig farms, poultry and mosquito infestation in Asia Pacific region has become one of the factors driving the growth of JE vaccine market in tropical region.

JE vaccine can be used for children and adults above 2 months of age. Vaccination is recommended for travelers to Asia who meet any of the following conditions: intend to stay in JE-prone areas for at least 1 month; will travel for less than 1 month but will travel to rural areas and spend most of their time outdoors; are traveling to JE-prone areas; or are uncertain about their trip. Laboratory workers who may be at risk of exposure to JE virus should also receive the vaccine. Thus, increased safety awareness will further contribute to the development of the demand for JE vaccine.

Region Overview:

Asia Pacific had the highest growth rate of all regions.

Company Overview:

Chengdu institute of biologica is one of the major players operating in the Japanese Encephalitis (JE) Vaccine market, holding a share of 14.95% in 2020.

Chengdu Institute of Biology (CIB), founded in 1958, is a public academic institution directly under the Chinese Academy of Sciences (CAS). As one of the first selected units for Knowledge Innovation Program of CAS, CIB has been dedicated in research in term of biodiversity conservation and sustainable uses of bioresources, and is scientific foundation, technical support and decision-making basis for ecological environment construction and biodiversity conservation of the upper reaches of Yangtze River as well as formation and promotion of strategic emerging biological industry.

CIB has developed substantial and solid cooperation with universities and scientific research institution in over 20 countries, e.g., US, UK, Germany，France and Russia. Strategic partnership with domestic universities, institutions and companies has been established also.

Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers and various vaccines in development, including unique vaccines against Lyme disease, chikungunya and COVID-19.

The Company has operations in Austria, Sweden, the United Kingdom, France, Canada and the US.

Segmentation Overview:

Among different product types, Live Attenuated Vaccine segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Public segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Japanese Encephalitis (JE) Vaccine market covered in Chapter 3:

Biological E. Limited
Bharat Biotech
Valneva
Liaoning Chengda
Chengdu institute of biologica
Wuhan Institute of Biological
Sanofi

In Chapter 4 and Chapter 14.2, on the basis of types, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2029 is primarily split into:

Inactivated Vaccine
Live Attenuated Vaccine

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2029 covers:

Public
Private

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)